Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitolactol
- Development stage
- Phase 3
- Lead developer
- Chinoin
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mitolactol is a synthetic derivative of hexitol and an oral alkylating agent with antineoplastic and radiosensitizing properties. It acts primarily by alkylating DNA via actual or derived epoxide groups, leading to inhibition of DNA and RNA synthesis, which results in cytotoxic effects on cancer cells. Mitolactol has been investigated for the treatment of various cancers, including brain and central nervous system tumors, as well as cervical cancer. Its unique features include oral bioavailability compared to other alkylating agents that may require intravenous administration[1][2][4][5][6][7].
- Brand names
- ElobromolMitolactol-Chinoin
- Other names
- dibromodulcitolbromoalcoholmetholactoleDBD
02
Targets
DNA
Beyond the preview
Go deeper on mitolactol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitolactol.